Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study)

NCT01335932 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01335932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01335932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study)
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
March 10, 2011
Completion date
October 28, 2016
Enrollment
160 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury, acute respiratory distress syndrome, respiratory failure